Table 3.
Evolutive characteristics of the suggestive-or-compatible challenge MMP patients who discontinued gliptin (dechallenge) vs. those who continued it (no dechallenge).a
| Characteristic | Overall | Dechallenge | No dechallenge | |||
|---|---|---|---|---|---|---|
| n = 17 | Missing | n = 11 | Missing | n = 6 | Missing | |
| Weeks, median (range) | ||||||
| Gliptin-onset-to-MMP-diagnosis interval | 136 (4–588) | 0 | 36 (4–232) | 0 | 136 (4–588) | 0 |
| Time to first complete remission | 8 (0–36) | 7 | 8 (2–16) | 3 | 18 (0–36) | 4 |
| Length of follow-up | 40 (0–164) | 0 | 32 (0–104) | 0 | 78 (4–164) | 0 |
| Initial treatment | 17 | 1 | 11 | 0 | 5 | 1 |
| Dapsone | 11 | 8 (73%) | 3 (50%) | |||
| Doxycyclin | 6 | 4 (36%) | 2 (33%) | |||
| Cyclophosphamide | 5 | 2 (18%) | 3 (50%) | |||
| Rituximab | 2 | 2 (18%) | 0 | |||
| At the first year of follow-up, patients, n (%) | ||||||
| Relapses/flares | ||||||
| Yes | 4 (31%) | 4 | 2b (22%) | 2 | 2 (50%) | 2 |
| No | 9 (69%) | 7c (78%) | 2 (50%) | |||
| Complete remission | ||||||
| Yes | 9 (82%) | 6 | 7 (88%) | 3 | 2 (66%) | 3 |
| No | 2 (18%) | 1 (13%) | 1 (33%) | |||
| Deaths | ||||||
| Yes | 0 | 6 | 0 | 3 | 0 | 3 |
| No | 11 (100%) | (100%) | 3 (100%) | |||
MMP, mucous membrane pemphigoid.
aThe dechallenge group stopped gliptin intake during the first year of follow-up; the no-dechallenge group was still taking gliptin at 1 year of follow-up.
bOne relapsed before and one after stopping gliptin.
cOne relapsed after 1 year of follow-up and a rechallenge.